{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:04:49Z","timestamp":1788519889788,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Optimizing antifungal therapy is important to improve outcomes in severely immunocompromised patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We analysed the in vitro interaction between pulmonary surfactant and antifungal agents used for management of invasive pulmonary aspergillosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Amphotericin B formulations, mould-active triazoles and echinocandins were tested in vitro against 24 clinical isolates of different Aspergillus spp. with and without the addition of a commercial porcine surfactant (Curosurf\u00ae; Poractant alfa, Nycomed, Austria). The data are presented as MIC or minimum effective concentration (MEC) ranges, as MIC or MEC values that inhibited 90% of the isolates (MIC90 or MEC90) and as geometric mean (GM) MIC or MEC values.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For amphotericin B products, addition of surfactant to a final concentration of 10% led to a statistically significant reduction of the GM MIC for all Aspergillus isolates tested after 24 h (0.765 versus 0.552 mg\/L; P &amp;lt; 0.05). For the mould-active triazoles, addition of 10% surfactant resulted in a significantly higher GM MIC at 48 h (0.625 versus 0.898 mg\/L; P &amp;lt; 0.05). For the echinocandins, the addition of 10% surfactant led to a significantly higher GM MEC after both 24 h (0.409 versus 0.6532 mg\/L; P &amp;lt; 0.01) and 48 h (0.527 versus 0.9378 mg\/L; P &amp;lt; 0.01). There were no meaningful differences between individual members of the three existing classes of antifungal agents or between the different Aspergillus spp. tested.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Using EUCAST methodology, addition of porcine surfactant up to a concentration of 10% had a minor, and presumably non-relevant, impact on the in vitro activity of antifungal agents used in prophylaxis and treatment of invasive pulmonary aspergillosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab422","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T12:08:34Z","timestamp":1635768514000},"page":"695-698","source":"Crossref","is-referenced-by-count":4,"title":["Interaction <i>in vitro<\/i> of pulmonary surfactant with antifungal agents used for treatment and prevention of invasive aspergillosis"],"prefix":"10.1093","volume":"77","author":[{"given":"Kerstin K","family":"Rauwolf","sequence":"first","affiliation":[{"name":"Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Paediatric Haematology\/Oncology, University Children\u2019s Hospital M\u00fcnster, M\u00fcnster, Germany"},{"name":"Division of Pediatric Oncology, University Children's Hospital, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hoertnagl","sequence":"additional","affiliation":[{"name":"Institute of Hygiene and Medical Microbiology, Christian Doppler Laboratory for Invasive Fungal Infections, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Lass-Floerl","sequence":"additional","affiliation":[{"name":"Institute of Hygiene and Medical Microbiology, Christian Doppler Laboratory for Invasive Fungal Infections, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-393X","authenticated-orcid":false,"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Paediatric Haematology\/Oncology, University Children\u2019s Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"2022022312592116700_dkab422-B1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-0039-3401990","article-title":"Invasive pulmonary aspergillosis","volume":"41","author":"Ledoux","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"2022022312592116700_dkab422-B2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mib.2021.04.006","article-title":"Invasive pulmonary aspergillosis associated with viral pneumonitis","volume":"62","author":"Dewi","year":"2021","journal-title":"Curr Opin Microbiol"},{"key":"2022022312592116700_dkab422-B3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.idc.2021.03.008","article-title":"Aspergillosis: epidemiology, diagnosis, and treatment","volume":"35","author":"Cadena","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"2022022312592116700_dkab422-B4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0031-1295726","article-title":"Antifungal PK\/PD considerations in fungal pulmonary infections","volume":"32","author":"Lepak","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"2022022312592116700_dkab422-B5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11592900-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2022022312592116700_dkab422-B6","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1128\/AAC.42.10.2569","article-title":"Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level","volume":"42","author":"Jahn","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2022022312592116700_dkab422-B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0732-8893(00)00236-4","article-title":"The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus","volume":"39","author":"Chiller","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022022312592116700_dkab422-B8","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"2022022312592116700_dkab422-B9","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1128\/AAC.00778-13","article-title":"Effect of pulmonary surfactant on antimicrobial activity in vitro","volume":"57","author":"Schwameis","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022022312592116700_dkab422-B10","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbamem.2017.04.019","article-title":"Pulmonary surfactant and nanocarriers: toxicity versus combined nanomedical applications","volume":"1859","author":"Hildago","year":"2017","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"2022022312592116700_dkab422-B11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1128\/AAC.00875-07","article-title":"Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics","volume":"52","author":"Gotfried","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2022022312592116700_dkab422-B12","author":"EUCAST. Methods in Fungi"},{"key":"2022022312592116700_dkab422-B13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/JCM.41.1.403-409.2003","article-title":"Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991)","volume":"41","author":"Espinel-Ingroff","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2022022312592116700_dkab422-B14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1469-0691.2007.01790.x","article-title":"Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST)","volume":"13","author":"Cuenca-Estrella","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"2022022312592116700_dkab422-B15","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1080\/13693780500051919","article-title":"The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence","volume":"43","author":"Clemons","year":"2005","journal-title":"Med Mycol"},{"key":"2022022312592116700_dkab422-B16","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1469-0691.2009.02913.x","article-title":"Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside","volume":"15","author":"Hope","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2022022312592116700_dkab422-B17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/jof6040198","article-title":"Modeling invasive aspergillosis: how close are predicted antifungal targets?","volume":"6","author":"Walsh","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2022022312592116700_dkab422-B18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jac\/30.3.249","article-title":"The site concentrations of antimicrobial agents in the lung","volume":"30","author":"Honeybourne","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"2022022312592116700_dkab422-B19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0891-5520(05)70202-6","article-title":"Intrapulmonary concentrations of antimicrobial agents","volume":"12","author":"Nix","year":"1998","journal-title":"Infect Dis Clin North Amer"},{"key":"2022022312592116700_dkab422-B20","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00241-06","article-title":"Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations","volume":"50","author":"Groll","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022022312592116700_dkab422-B21","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1128\/AAC.46.6.1974-1976.2002","article-title":"Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus","volume":"46","author":"Roilides","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2022022312592116700_dkab422-B22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.micinf.2003.12.010","article-title":"Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus","volume":"6","author":"Choi","year":"2004","journal-title":"Microbes Infect"},{"key":"2022022312592116700_dkab422-B23","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1128\/AAC.00637-11","article-title":"Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis","volume":"55","author":"Campoli","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022022312592116700_dkab422-B24","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/infdis\/jit358","article-title":"Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis","volume":"208","author":"Campoli","year":"2013","journal-title":"J Infect Dis"},{"key":"2022022312592116700_dkab422-B25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fcimb.2020.00229","article-title":"Surfactant protein D recognizes multiple fungal ligands: a key step to initiate and intensify the anti-fungal host defense","volume":"10","author":"Madan","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2022022312592116700_dkab422-B26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1476-5381.1996.tb15442.x","article-title":"Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity","volume":"118","author":"van 't Veen","year":"1996","journal-title":"Br J Pharmacol"},{"key":"2022022312592116700_dkab422-B27","first-page":"383","article-title":"Amphotericin B and pulmonary surfactant","volume":"3","author":"Griese","year":"1998","journal-title":"Eur J Med Res"},{"key":"2022022312592116700_dkab422-B28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.healun.2012.11.013","article-title":"Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant","volume":"32","author":"Monforte","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"2022022312592116700_dkab422-B29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0005-2736(90)90305-8","article-title":"The effect of surfactants on the aggregation state of amphotericin B","volume":"1030","author":"Tancr\u00e8de","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"2022022312592116700_dkab422-B30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","article-title":"Aerosolized delivery of antifungal agents","volume":"4","author":"Le","year":"2010","journal-title":"Curr Fungal Infect Rep"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/3\/695\/42587142\/dkab422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/3\/695\/42587142\/dkab422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T15:20:03Z","timestamp":1645629603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/3\/695\/6425642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,11,11]]},"published-print":{"date-parts":[[2022,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab422","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,2]]},"published":{"date-parts":[[2021,11,11]]}}}